Oppenheimer cuts Spruce Biosciences shares target cut to $4 on trial results By Investing.com
© Reuters. On Thursday, Oppenheimer adjusted its outlook on Spruce Biosciences, Inc. (NASDAQ:SPRB), reducing the price target to $4 for ...
© Reuters. On Thursday, Oppenheimer adjusted its outlook on Spruce Biosciences, Inc. (NASDAQ:SPRB), reducing the price target to $4 for ...
Earlier this month we dissected the ongoing battle between investor activist Carl Icahn and the second-biggest holding in our Nanalyze ...
Cytek Biosciences, Inc. (NASDAQ:CTKB) Q1 2023 Earnings Conference Call May 9, 2023 4:30 PM ET Company Participants Paul Goodson - ...
AzmanJaka/E+ via Getty Images Arcus Biosciences (NYSE:RCUS) is a biopharmaceutical company specializing in cancer therapeutics that are operating at the ...
Anyone who remembers the days of Flamel and Sky Pharma knows that the promise of nano drug delivery never really ...
One in every of Warren Buffett’s many notable quotes is that “in case you’ve been taking part in poker for ...
Copyright © 2022 - Index Investing News.
Index Investing News is not responsible for the content of external sites.